📊 Ticker Highlight: AMD (Advanced Micro Devices)
1. One-Year Oversold — RSI below 30 & Bounce
RSI (14-day) dipped slightly under 30 around late May 2025, triggering classic oversold alert. It has since rebounded toward neutral territory (~40), suggesting a reversal directorstalkinterviews.com+9stockinvest.us+9tickertape.in+9.
Reasoning: The drop coincided with sector weakness and tech rotation, but bounce suggests accumulation is starting.
2. MACD at Valley & Reversal Signal
According to StockInvest, AMD’s 3-month MACD recently issued a bullish crossover from a valley position, indicating upward momentum stockmonitor.com+2stockinvest.us+2indmoney.com+2.
Supporting Indicators: The RSI bounce and MACD pivot solidify the setup for a sustained move.
3. Institutional Ownership & Inflows
As of Q2 2025, AMD is highly institutional—Vanguard, BlackRock, State Street among top holders directorstalkinterviews.com+6tradingview.com+6tradingview.com+6.
In late May through early June, granular 13F filings show:
Jane Street added ~216,900 shares on May 19
Goldman Sachs added ~1,048,600 shares on May 16
Intech, UBS AM, and Parkman Healthcare all increased holdings marketbeat.com+1nasdaq.com+1.
Reasoning: Heavy inflows indicate institutional conviction coming back post-dip.
4. Insider Buying
No recent high-level insider buys detected for AMD. However, insiders tend to trade under 10b5-1 plans, common in tech.
(No material buys; no SEC filings identified for insider purchases.)
5. Analyst Upgrades & Price Targets
Recent publications (e.g., Director’s Talk) show analyst consensus price target around $140–$150, about 15–25% above current ~$123 wsj.com+14directorstalkinterviews.com+14humblestudentofthemarkets.com+14investing.com.
Reasoning: Upgrades reflect excitement over AI/data center demand and strong product roadmap.
6. Near-Term Catalysts
2025 Q2 Earnings expected late July; bullish guidance for revenue and margin likely.
Continued data-center CPU/GPU launches (MI300/Zen5 refresh) scheduled mid-to-late 2025.
Reasoning: Earnings and new product cycle can re-ignite investor interest.
7. Recession-Resistance & Emerging Tech
AMD leverages secular trends in AI, cloud computing, gaming, HPC.
Demand for GPUs/CPUs for AI inference remains strong, less sensitive to macro downturns.
Reasoning: Diversified high-growth end markets buffer macro pressure.
8. Fundamentals
Revenue growth remains high: ~30% YoY. Fundamentals strong
(e.g., Ryzen/EPYC adoption).Cash flow robust, manageable debt; healthy cash reserves (per Q1 earnings) screener.in+1stockmonitor.com+1.
Reasoning: Free cash flow and operating leverage support long-term sustainability.
9. Liquid Options: Skew to Calls
Weekly/monthly options show heavy call interest over puts.
Major strikes: $130, $135, $140 monthly calls hold thousands of contracts (check live chain).
Reasoning: Call-skew indicates bullish trader positioning and leverage demand.
10. Recent Drop & Setup
AMD fell ~15% since April peak (over broad tech selloff).
Since early June, RSI/MACD bounce + options flow and institutional DCF accumulation signal dust-settled reversal tradingview.com+1tradingview.com+1.
11. LEAPS ITM Call Opportunity
High liquidity on 18‑ to 24‑month LEAPS (e.g., Jan 2027 $100–$110 strike).
These strikes carry Delta ~0.75–0.85—ideal for leveraged exposure to long-term growth.
Reasoning: Efficient exposure with lower theta decay over horizon.
🧩 Thesis Summary
AMD looks attractive technically and fundamentally:
Oversold RSI recovered, MACD bullish.
Institutional accumulation confirms confidence.
Product cycle (AI/data center) supports mid‑term upside.
Long-dated call skew reflects positive sentiment.
Anticipate a range of catalysts (earnings, product releases) in July–September 2025 to drive price action.
📈 Trade Strategy
Stock Entry: $120–$125
Targets:
• Tier 1: $140 (~15% gain) — near-term earnings catalyst
• Tier 2: $150–$155 (~25–30%) — post-launch/data center adoption
Stop Loss: $110 (below recent swing low) — limits downside if sentiment shifts.
🕒 Jan 2027 LEAPS ITM Call Strategy
Select: $100 strike, Jan 2027 expiration, Delta ~0.75.
Entry zone: Option premium ~$41 / contract (depending on IV).
Profit Tiers:
• Tier 1: Premium ↗ $60 (+50%) by mid 2026 (post-upgrades)
• Tier 2: Premium ↗ $80 (+100%) by end 2026 (AI ramp + earnings momentum)Time‑based Stop: Exit by mid 2026 if no 20% move above entry premium achieved.
Reasoning: Balances growth leverage (AI/data center cycle) with defined capital at risk and lower theta decay.
⚠️ Capital Allocation Warning & Risk Management Advisory
Do not risk more than 2% of your total capital on this or any single trade.
Both options and biotech equities carry high volatility and inherent risk. While long-term LEAPS trades can provide leverage with limited risk, and stock positions may offer high upside during rebounds, proper capital management is critical:
💡 Position sizing rule: Limit your total exposure on CRSP (stock or LEAPS) to no more than 2% of your portfolio.
🛑 Use defined-risk setups and avoid emotional averaging down.
📉 If CRSP breaks below key technical support or catalysts fail to materialize, have a clear exit strategy in place.
Learn more about stock options in our Stock Options Education Series.
📜 Disclaimer
This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. Past performance is not indicative of future results. You are solely responsible for any investment decisions you make.
